Highlight


	Orphan Europe Filed Carbaglu NDA with the FDA in the U.S. The 21/04/2008 at 12:11:17 Recordati announced the submission to the U.S. FDA by Orphan Europe (a Recordati group company) of an Original New Drug Application (NDA) for Carbaglu® (carglumic acid). The NDA provides for the safe and effective use of Carbaglu® in the treatment of hyperammonaemia due to an autosomal genetic disorder resulting in the deficiency of the liver enzyme N-acetylglutamate synthase (NAGS deficiency). Read the news >>

Orphan Europe provides treatment for patients suffering from rare diseases all over the world. Read more about the different diseases here.

Orphan Europe has been developing and distributing orphan drugs since 1990 and has today an extensive product portfolio. Read more about some of the orphan medicinal products provided by Orphan Europe.

Provides high-quality, innovative science education for healthcare personnel involved in the diagnosis and management of patients affected by rare diseases.

On the top

Orphan Europe is recruiting an International Product Manager based at the headquarters in Paris

Meet Orphan Europe at the The 5th International Cystinosis Conference

Highlight

Orphan Europe Filed Carbaglu NDA with the FDA in the U.S.